PriceTargets.com logo

Agenus - AGEN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.83
  • Forecasted Upside: 244.73%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.56 As of 02/7/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agenus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGEN

Analyst Price Target is $8.83
▲ +244.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $8.83, with a high forecast of $14.00 and a low forecast of $5.00. The average price target represents a 244.73% upside from the last price of $2.56.

This chart shows the closing price for AGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$8.30Low
12/8/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$8.30Low
9/28/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$5.00Low
3/3/2022B. RileyLower Target$11.00 ➝ $8.00Medium
3/2/2022HC WainwrightBoost TargetBuy$12.00 ➝ $14.00High
12/16/2021HC WainwrightInitiated CoverageBuy$12.00High
10/25/2021B. RileyReiterated RatingBuy$12.00 ➝ $11.00High
9/7/2021B. RileyBoost TargetBuy$11.00 ➝ $12.00High
1/15/2021B. RileyReiterated RatingBuy$8.00High
12/10/2020B. RileyReiterated RatingBuy$8.00Medium
9/23/2020William BlairReiterated RatingBuyLow
9/18/2020Jefferies Financial GroupBoost TargetBuy$5.00 ➝ $8.00Medium
6/22/2020B. RileyReiterated RatingBuy$6.00Low
6/5/2020B. RileyReiterated RatingBuy$6.00Low
5/29/2020B. RileyReiterated RatingBuy$6.00High
5/22/2020B. RileyReiterated RatingBuy$6.00Low
12/20/2019B. RileyInitiated CoverageBuy$6.00High
11/19/2019B. RileyInitiated CoverageBuy$6.00Low
4/22/2019B. RileyInitiated CoverageBuy ➝ Buy$5.00 ➝ $5.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
7/12/2022
  • 5 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 1 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
Mentions as of
10/10/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/9/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/8/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Agenus logo
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $2.56
Low: $2.48
High: $2.61

50 Day Range

MA: $2.56
Low: $2.17
High: $2.97

52 Week Range

Now: $2.56
Low: $1.25
High: $3.37

Volume

2,969,066 shs

Average Volume

4,115,728 shs

Market Capitalization

$780.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Agenus?

The following sell-side analysts have issued stock ratings on Agenus in the last twelve months: B. Riley, EF Hutton Acquisition Co. I, HC Wainwright, StockNews.com, Sumitomo Mitsui Financial Group, Inc., and TheStreet.
View the latest analyst ratings for AGEN.

What is the current price target for Agenus?

4 Wall Street analysts have set twelve-month price targets for Agenus in the last year. Their average twelve-month price target is $8.83, suggesting a possible upside of 244.7%. HC Wainwright has the highest price target set, predicting AGEN will reach $14.00 in the next twelve months. Sumitomo Mitsui Financial Group, Inc. has the lowest price target set, forecasting a price of $5.00 for Agenus in the next year.
View the latest price targets for AGEN.

What is the current consensus analyst rating for Agenus?

Agenus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGEN will outperform the market and that investors should add to their positions of Agenus.
View the latest ratings for AGEN.

What other companies compete with Agenus?

Other companies that are similar to Agenus include Novavax, Sangamo Therapeutics, BioCryst Pharmaceuticals, iTeos Therapeutics and ADMA Biologics. Learn More about companies similar to Agenus.

How do I contact Agenus' investor relations team?

Agenus' physical mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 674-4400 and its investor relations email address is [email protected] The official website for Agenus is agenusbio.com. Learn More about contacing Agenus investor relations.